FDA Issues Warning Letter to Baxter’s Drug Manufacturing Plant Acquired in Claris Buy
The agency has issued a warning letter for cGMP violations at a drug manufacturing facility in Ahmedabad, India, that Baxter gained through its acquisition of Claris Injectables.
In a warning letter issued by FDA on July 5, 2018, the agency found cGMP violations at Baxter International’s drug manufacturing facility in Ahmedabad, India, which the company got last year with its July 2017 acquisition of Claris Injectables. The warning letter is based on FDA’s inspection of the facility from July 27, 2017 to August 4, 2017.
During the inspection, investigators observed defective batches that were not thoroughly investigated; incomplete batch production and control records; and lack of good building maintenance where manufacturing, processing, packaging, or drug storage took place.
In response to the letter, Baxter is required to provide an independent review of its maintenance programs for both facilities and equipment, a corrective action preventive action (CAPA) plan, and a data integrity remediation strategy that includes a comprehensive investigation into data integrity lapses; a current risk assessment on drug quality; and a management strategy to ensure the reliability and completeness of all data generated by the company.
FDA also noted that it has cited similar cGMP violations at the Ahmedabad facility in a previous warning letter on November 1, 2010.
Source: FDA
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
